FDA Proposes Ban on Unregulated Desiccated Thyroid Extract (DTE) for Hypothyroidism

Strategic Insights -

The American Thyroid Association recommends synthetic levothyroxine as the standard therapy for hypothyroidism, but a subset of patients opt for desiccated thyroid extract (DTE), an unregulated product that has never been approved by the FDA. The FDA has issued a statement of concern regarding the unregulated nature of DTE and has proposed banning it from the marketplace. The American Thyroid Association supports evidence-based patient guidance and regulations that ensure medication purity and consistency.

Key Takeaways:

  • The American Thyroid Association recommends synthetic levothyroxine as the standard therapy for hypothyroidism, but DTE is still used by some patients as a treatment for hypothyroidism.
  • DTE is an unregulated product that has never been approved by the FDA, despite being used as a treatment for hypothyroidism.
  • The FDA has issued a statement of concern regarding the unregulated nature of DTE and has proposed banning it from the marketplace.
  • The American Thyroid Association supports evidence-based patient guidance and regulations that ensure medication purity and consistency.
  • The FDA is proposing a 12-month transition period for patients currently taking DTE to switch to FDA-approved products.
  • The American Thyroid Association supports a regulatory approach that ensures the highest standards for DTE safety and reliability.
  • The American Thyroid Association is committed to working with the FDA to ensure that safe and effective personalized hypothyroidism treatment remains available to all.

Statistics:

  • Over 1,700 members of the American Thyroid Association are from 70 countries around the world. (Source: American Thyroid Association)
  • The American Thyroid Association promotes thyroid awareness and information through its online Clinical Thyroidology for the Public, which is distributed free of charge to over 12,000 patients and public subscribers. (Source: American Thyroid Association)
  • The American Thyroid Association received a statement of concern from the FDA regarding the unregulated nature of DTE on August 6, 2025. (Source: Original Press Release)
  • The FDA proposes a 12-month transition period for patients currently taking DTE to switch to FDA-approved products. (Source: Original Press Release)
  • The American Thyroid Association website receives over 12,000 visitors per month. (Source: American Thyroid Association)

Sources:

  • American Thyroid Association
  • [Original Press Release]